



Business Overview

SELIC and its subsidiary have engaged in manufacturer, distributor including research and development as following businesses:

- Adhesive Business
- Self-Adhesive Label Business
- Consumer Healthcare

Financial Statement

	2022	2021	2020	2019
--	------	------	------	------

Income Statement (MB)

Revenues	1,624.70	1,466.03	1,257.89	1,396.98
Expenses	1,543.38	1,340.43	1,119.27	1,252.33
Net Profit (Loss)	40.25	81.53	89.31	85.81

Balance Sheet (MB)

Assets	2,781.94	1,756.92	1,618.55	1,593.50
Liabilities	1,547.08	1,088.83	1,096.93	1,161.04
Shareholders' Equity	959.47	668.08	521.61	432.46

Cash Flow (MB)

Operating	128.32	105.50	207.91	148.40
Investing	-615.47	-100.20	-11.51	-803.26
Financing	566.40	-58.89	-161.73	561.16

Financial Ratio


EPS (Baht)	0.08	0.18	0.27	0.30
GP Margin (%)	22.00	24.20	25.46	24.46
NP Margin (%)	2.44	5.56	7.10	6.14
D/E Ratio (x)	1.25	1.63	2.10	2.68
ROE (%)	4.95	13.71	18.72	21.95
ROA (%)	3.32	7.44	8.78	13.61

Business Plan

Directions and operation plan in 2022

- Growth Driver:** Maintain sector targeting to grow, Expand market application through New Product Development (NPD) and Investment project pipelines through Merge and Acquisition (M&A), Joint Venture (JV)
- Profitability Driver:** Leverage R&D to build gross profit, Supply chain management to get cost avoidance, and Efficiency operation.
- Sustainability Development:** Sustainable materials for customer's supply chain, Green product NPD through innovation, Energy and waste management.

Sustainable Development Plan



Business Highlight

- Incubation Center Project at the Thailand Science Park, through a project with the Thailand Board of Investment.
- Invested in Meticuly Company Ltd., which manufactures and services strong and high-precision bone implants designed for individual patients.
- Invested in Devakam Apothecary Hall Co., Ltd, a manufacturer and distributor of relieving-muscle-pain products under the brand name "Namman Muay" and established DVK Healthcare Co., Ltd. to invest in the production and distribution of healthcare products under brand of Neoplast™ and Neobun™.

Performance and Analysis

Business Performance Summary

<https://weblink.set.or.th/dat/news/202302/23023246.pdf>

Key Milestones

- 2022:** Invested in Devakam Apothecary Hall Co., Ltd ("Devakam") by purchasing 50% of ordinary shares after Devakam capital increase and Group obtained control over Devakam. Then, Devakam established DVK Healthcare Co., Ltd ("DHC") by holding 100% in DHC causing the Group will enable to expand the business growth, penetrate healthcare market, and expand its business channels to B2C model.
- 2021:** Changed the shareholding and management structure of PMC Label Materials Limited (PMCT) Thailand, by moving PMC Label Materials Pte Ltd, Singapore, under the shareholding and management of PMCT.
- 2020:** Opened a distribution center in Australia under the name, Selic Australia Pty Ltd., where SELIC has 100% shareholding of the company's listed capital, and in Malaysia under the name, PMC Label Materials Sdn Bhd. (PMCM), where SELIC holds indirect shares through a PMCL subsidiary, in order to support the market expansion of SELIC and its subsidiary companies.
- 2019:** Acquired and received controlling authority of PMC Label Materials Limited (PMCT) Thailand and PMC Label Materials Pte Ltd, Singapore.
- 2016:** Became a publicly listed company and completed our IPO with a registered capital of 40 million Baht.

Risk Management Policy

The company recognizes the importance of sustainable risk management, as this ensures that the company is able to meet our objectives and targets, build trust among stakeholders, and minimize any potential future losses. The company has established a risk management policy that focuses on managing risks across all business activities, and strives to embed risk management as part of our organizational culture. The company regularly reviews risks related to all aspects of business operations, and analyzes internal and external risk factors that could impact the business. Through this approach, the company is able to respond to any risks that might occur and identify approaches to manage and minimize all categories of risk, to ensure that such risks fall within manageable and acceptable levels.

Recent Awards and Recognitions

- List of ESG Emerging 2022 from Thaipat Institute
- List of Thailand Sustainability Investment 2022 from the Stock Exchange of Thailand
- SET Awards 2022: Commended Sustainability Awards from the Stock Exchange of Thailand
- CAC Change Agent Award 2022 from Thai Private Sector Collective Action Against Corruption-CAC
- Sustainability Disclosure Recognition 2022 from Thaipat Institute

Revenue Structure



Stock Information

mai / INDUS



as of 30/12/22	SELIC	INDUS	mai
P/E (X)	36.30	22.63	54.51
P/BV (X)	1.77	1.73	2.98
Dividend yield (%)	0.14	2.45	1.14

	30/12/22	30/12/21	30/12/20
Market Cap (MB)	1,691.07	1,465.59	660.00
Price (B/Share)	2.86	3.20	2.00
P/E (X)	36.30	15.75	8.25
P/BV (X)	1.77	2.23	1.32


CG Report:



Company Rating: THSI

Major Shareholders

as of 30/12/2022



Company Information and Contact

<http://seliccorp.com/>
 investorRelation@seliccorp.com
 0-2807-3347-9
 270 Liaphklongphasicharoenfangtai Road, Nongkhaem Bangkok 10160
 Other Trading Info :
https://www.settrade.com/C04_01_stock_quote_p1.jsp?txtSymbol=SELIC

Remarks: This document is prepared by the listed company and aimed to disseminate the listed company's information to investors for only investment decision support. The listed company does not give investment advice or recommendation regarding the listed company's securities. Before making investment decisions, investors should study additional information and seek advice from relevant professionals. In no event shall the listed company be responsible for any loss or damage arising from the use of the information contained herein. The listed company reserves the right to amend the content specified in this document without prior notice. Unless otherwise permitted by the listed company, copy, modification, or dissemination of this document or the content contained herein is prohibited. In case there is any questions regarding the listed company's information, the investors may seek for additional information from the report or information which the listed company has disclosed through the Office of the Securities and Exchange Commission's and/or the Stock Exchange of Thailand's channel.